> ## Content Index
> Fetch the complete content index at: https://chinapharmadesk.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Zhaoke clears once-nightly cyclosporine dry-eye gel in China—three years after a withdrawn NDA and too late for 2026 NRDL
- URL: https://chinapharmadesk.com/zhaoke-cyclosporine-gel-china-dry-eye-approval/
- Published: 2026-11-13T16:23:11.000Z
- Updated: 2026-11-15T02:54:02.000Z
- Description: Zhaoke Ophthalmology (06622.HK) won China NMPA approval on Nov 10 for once-nightly Cyclosporine Ophthalmic Gel (Jingyouling) after Phase 3 COSMO, facing a self-pay 2027 race against Xingqi (300573.SZ).
- Author: Lin Yi
- Tags: Desk brief, Pipeline, Market Access, Regulation

Chapter 18A biotech Zhaoke Ophthalmology Limited (`HKEX: 06622`) announced on November 13, 2026 that China’s National Medical Products Administration (NMPA) approved its self-developed Cyclosporine Ophthalmic Gel (`Jingyouling`) on November 10 to increase tear production in patients with dry eye disease. Disclosed in an [evening inside-information filing](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1113/2026111300988.pdf?ref=chinapharmadesk.com) (`06622.HK`, 18:41 HKT), the decision closes a three-year regulatory detour after Zhaoke voluntarily withdrew its initial NDA in October 2023 and refiled in May 2025 (`CXHS2500052`). Because the clearance arrived four months after the National Healthcare Security Administration (NHSA) cut unapproved pre-applicants from the 2026 [National Reimbursement Drug List (NRDL)](https://chinapharmadesk.com/china-pharma-glossary/) formal review, Zhaoke must spend 2027 pitching a self-pay once-nightly gel against Shenyang Xingqi Ophthalmic’s (`SZSE: 300573`) NRDL-reimbursed twice-daily cyclosporine drops (`Zirun`).

## From a 2023 NDA withdrawal to COSMO’s two-week onset claim

Jingyouling is China’s first approved ophthalmic hydrogel formulation of cyclosporine and Zhaoke’s first internally developed innovative drug to reach the market. Combining nanomicellar solubilization with a preservative-free mucoadhesive hydrogel, the formulation extends corneal residence time so patients dose **once daily at bedtime** rather than twice daily during waking hours.

Zhaoke originally completed its 41-center, 644-patient Chinese Phase 3 `COSMO` trial earlier in the decade, only to withdraw its first NDA in October 2023 after CDE updated its technical review expectations for dry-eye endpoints. Following additional post-hoc analyses, pre-NDA consultations with CDE, and initiation of a supplementary 360-patient Chinese Phase 3 study ([NCT06766357](https://clinicaltrials.gov/study/NCT06766357?ref=chinapharmadesk.com)), NMPA re-accepted the NDA in May 2025—one month before the U.S. FDA cleared Zhaoke’s Phase 3 IND using the Chinese `COSMO` package as supportive evidence.

In `COSMO` (`n = 644` moderate-to-severe dry eye patients randomized to once-nightly gel or vehicle), the approved dataset showed:

- **Primary Day-84 sign endpoint:** **73.7%** of patients on Cyclosporine Ophthalmic Gel achieved a ≥1-point improvement from baseline in Inferior Corneal Staining Score (ICSS), compared with **53.2%** on vehicle control (*P* < 0.0001).
- **Two-week onset:** Statistically significant separation over vehicle emerged by **Day 14** (*P* < 0.05) across ICSS, Oxford corneal/conjunctival staining, and anesthetized Schirmer tear production, sustained through Day 84—contrasting with the four-to-eight-week lag typical of conventional cyclosporine emulsions.
- **Ocular tolerability:** Treatment-related ocular adverse events occurred in **12.5%** of gel recipients versus **5.4%** on vehicle, led by transient eye pain (**8.1%**, with all other ocular reactions below 3%) and zero drug-related serious adverse events.

## The 2027 commercial fault line: bedtime convenience vs. NRDL coverage

Winning NMPA approval solves Zhaoke’s regulatory overhang, but the timing creates an immediate reimbursement asymmetry across Chinese ophthalmology clinics and e-commerce pharmacies:

| Commercial Dimension      | Zhaoke (06622.HK) — Jingyouling Gel                                                                                                                                             | Shenyang Xingqi (300573.SZ) — Zirun Drops                                                                                                                                         |
| ------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| Formulation & schedule    | Preservative-free nanomicellar hydrogel; **once nightly at bedtime**                                                                                                            | 0.05% single-use nanoemulsion (0.4 mL: 0.2 mg); **twice daily, 12h apart**                                                                                                        |
| China approval & patent   | Approved November 10, 2026 (first domestic CsA gel)                                                                                                                             | Approved June 2020 ([composition patent to July 2039](https://www.nhsa.gov.cn/attach/Ypsn2025/YPSN202500037/YPSN202500037.pdf?ref=chinapharmadesk.com))                           |
| 2027 reimbursement status | **Out-of-pocket / commercial only** (dropped from [July 14, 2026 NHSA final review list](https://www.nhsa.gov.cn/art/2026/7/14/art%5F109%5F21421.html?ref=chinapharmadesk.com)) | **NRDL Class B** (“restricted to dry eye disease,” renewed in [2025 NRDL Notice No. 33](http://static.cninfo.com.cn/finalpage/2025-12-08/1224856671.PDF?ref=chinapharmadesk.com)) |

Earlier this summer, Zhaoke attempted to bridge that gap using NHSA’s pre-application (*yushenbao*) channel for pending NDAs, passing preliminary June screening; however, because final NMPA sign-off did not land before NHSA’s mid-July verification cutoff, Jingyouling was one of 18 outside-catalogue pre-applicants excluded from the [final July 14, 2026 formal review roster](https://bk.cnpharm.com/zgyyb/2026/07/18/app%5F325501.html?ref=chinapharmadesk.com).

Per Zhaoke’s [2026 interim report](https://www.hkexnews.hk/listedco/listconews/sehk/2026/0828/2026082803007%5Fc.pdf?ref=chinapharmadesk.com) (`06622.HK`), first-half product revenue stood at just RMB 17.6 million (approx. $2.4 million) against a RMB 122.6 million net loss, supported by RMB 715.8 million (approx. $99.4 million) in unpledged cash and term deposits (plus RMB 295.6 million in pledged bank balances) and four commercial lines at its Guangzhou Nansha plant, which also won [Australian TGA GMP certification on October 27](https://static.cninfo.com.cn/finalpage/2026-10-27/1225627475.PDF?ref=chinapharmadesk.com). Until Zhaoke enters the mid-2027 NRDL negotiation cycle, commercial traction will depend on out-of-pocket retail pricing, online prescription channels, and upcoming NMPA decisions on its two other filed flagship drugs—low-dose atropine (`NVK002`) and ophthalmic bevacizumab (`TAB014`)—alongside Gulf Cooperation Council (GCC) review in Saudi Arabia.